Core Scientific officer sells 10K shares in plan trade

Core Scientific, Inc. officer Todd M. Duchene sold 10,000 shares of Common Stock in an open-market transaction.

Rhea-AI Filing Summary

Core Scientific, Inc. officer Todd M. Duchene sold 10,000 shares of Common Stock in an open-market transaction. The sale, executed on April 27, 2026, was made at a weighted average price of $20.939 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025. Following this sale, Duchene directly holds 1,990,348 shares of Core Scientific common stock.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares

Net Sell 1 txn

Insider DUCHENE TODD M

Role See remarks

Sold 10,000 shs ($209K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,000	$20.939	$209K

Holdings After Transaction: Common Stock — 1,990,348 shares (Direct)

Footnotes (2)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.58 to $21.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Key Figures

Shares sold: 10,000 shares Weighted average sale price: $20.939 per share Price range of trades: $20.58–$21.26 per share +3 more

6 metrics

Shares sold 10,000 shares Open-market sale of Common Stock on April 27, 2026

Weighted average sale price $20.939 per share Average price for 10,000 shares sold

Price range of trades $20.58–$21.26 per share Range of individual sale prices in multiple transactions

Shares held after sale 1,990,348 shares Direct ownership following the reported transaction

Trading plan adoption date December 5, 2025 Adoption date of Rule 10b5-1 trading plan used for this sale

Transaction code S Sale in open market or private transaction, non-derivative

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, non-derivative, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

non-derivative financial

"transaction_type": "non-derivative""

transaction code "S" regulatory

"transaction_code": "S", "transaction_code_description": "Sale in open market or private transaction""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Core Scientific (CORZ) report for Todd M. Duchene?

Core Scientific reported that officer Todd M. Duchene sold 10,000 shares of Common Stock. The open-market sale occurred on April 27, 2026, at a weighted average price of $20.939 per share and was executed under a pre-arranged Rule 10b5-1 trading plan.

How many Core Scientific (CORZ) shares does Todd M. Duchene hold after this sale?

After selling 10,000 shares, Todd M. Duchene directly holds 1,990,348 shares of Core Scientific Common Stock. This remaining stake shows the transaction represents a small portion of his overall holdings, based on the figures disclosed in the Form 4 filing.

What price did Todd M. Duchene receive for his Core Scientific (CORZ) share sale?

The filing reports a weighted average sale price of $20.939 per share for the 10,000 Core Scientific shares. Footnotes explain the shares were sold in multiple trades between $20.58 and $21.26, with detailed trade data available on request from the reporting person.

Was the Core Scientific (CORZ) insider sale by Todd M. Duchene pre-planned?

Yes. The Form 4 states the transactions were effected under a Rule 10b5-1 trading plan adopted by Todd M. Duchene on December 5, 2025. Such plans allow insiders to schedule trades in advance, helping separate routine liquidity events from discretionary timing decisions.

What type of transaction did Todd M. Duchene execute in Core Scientific (CORZ) stock?

Todd M. Duchene executed an open-market sale of Common Stock, coded as “S” in the Form 4. This non-derivative transaction involved 10,000 shares and reflects a direct disposition rather than an option exercise, gift, or tax-withholding related transfer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/29/2026 - 04:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DUCHENE TODD M

(Last) (First) (Middle)

C/O CORE SCIENTIFIC, INC.

838 WALKER ROAD, SUITE 21-2105

(Street)

DOVER DELAWARE 19904

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Core Scientific, Inc./tx [ CORZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/27/2026		S(1)		10,000	D	$20.939(2)	1,990,348	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.58 to $21.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Remarks:

Chief Legal and Administrative Officer

	/s/ Todd DuChene	04/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)